0001179110-18-002466.txt : 20180221 0001179110-18-002466.hdr.sgml : 20180221 20180221160908 ACCESSION NUMBER: 0001179110-18-002466 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180216 FILED AS OF DATE: 20180221 DATE AS OF CHANGE: 20180221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quirk Gerald E CENTRAL INDEX KEY: 0001479603 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 18628471 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 MEMORIAL DRIVE STREET 2: SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 620 MEMORIAL DRIVE STREET 2: SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 edgar.xml FORM 4 - X0306 4 2018-02-16 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001479603 Quirk Gerald E C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE MA 02139 0 1 0 0 Chief Legal Officer Stock Option (right to buy) 10.09 2018-02-16 4 A 0 75000 0 A 2028-02-15 Common Stock 75000 75000 D Stock Option (right to buy) 13.30 2018-02-16 4 A 0 11666 0 A 2018-02-16 2026-09-26 Common Stock 11666 11666 D This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. On September 27, 2016, the Reporting Person was granted an option to purchase 35,000 shares of common stock. The option vests upon the achievement of performance-based criteria as determined by the Issuer's Board of Directors. On February 16, 2018, it was determined that certain of the performance criteria were met, resulting in vesting of the option as to 11,666 shares. /s/ Gerald E. Quirk 2018-02-20